Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung
Status:
Withdrawn
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects (good and bad) a tumor vaccine
(GM.CD40L) used in combination with Nivolumab will have on participants and their cancer.
Another purpose of the study is to find out the maximum tolerated dose of nivolumab in
combination with GM.CD40L vaccine. Investigators also want to find out if the combination of
GM.CD40L and nivolumab can boost the immune system of participants like you, and how their
immune system reacts, both before and after the treatment.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute